Funding sources and costs to deliver cardiac rehabilitation around the globe: Drivers and barriers.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 24 07 2018
revised: 05 09 2018
accepted: 25 10 2018
pubmed: 12 11 2018
medline: 25 7 2019
entrez: 12 11 2018
Statut: ppublish

Résumé

Cardiac rehabilitation (CR) reach is minimal globally, primarily due to financial factors. This study characterized CR funding sources, cost to patients to participate, cost to programs to serve patients, and the drivers of these costs. In this cross-sectional study, an online survey was administered to CR programs globally. Cardiac associations and local champions facilitated program identification. Costs in each country were reported using purchasing power parity (PPP). Results were compared by World Bank country income classification using generalized linear mixed models. 111/203 (54.68%) countries in the world offer CR, of which data were collected in 93 (83.78% country response rate; N = 1082 surveys, 32.0% program response rate). CR was most-often publicly funded (more in high-income countries [HICs]; p < .001), but in 60.20% of countries patients paid some or all of the cost. Funding source impacted capacity (p = .004), number of patients per exercise session (p < .001), personnel (p = .037), and functional capacity testing (p = .039). The median cost to serve 1 patient was $945.91PPP globally. In low and middle-income countries (LMICs), exercise equipment and stress testing were perceived as the most expensive delivery elements, with front-line personnel costs perceived as costlier in HICs (p = .003). Modifiable factors associated with higher costs included CR team composition (p = .001), stress testing (p = .002) and telemetry monitoring in HICs (p = .01), and not offering alternative models in LMICs (p = .02). Too many patients are paying out-of-pocket for CR, and more public funding is needed. Lower-cost delivery approaches are imperative, and include walk tests, task-shifting, and intensity monitoring via perceived exertion.

Sections du résumé

BACKGROUND BACKGROUND
Cardiac rehabilitation (CR) reach is minimal globally, primarily due to financial factors. This study characterized CR funding sources, cost to patients to participate, cost to programs to serve patients, and the drivers of these costs.
METHODS METHODS
In this cross-sectional study, an online survey was administered to CR programs globally. Cardiac associations and local champions facilitated program identification. Costs in each country were reported using purchasing power parity (PPP). Results were compared by World Bank country income classification using generalized linear mixed models.
RESULTS RESULTS
111/203 (54.68%) countries in the world offer CR, of which data were collected in 93 (83.78% country response rate; N = 1082 surveys, 32.0% program response rate). CR was most-often publicly funded (more in high-income countries [HICs]; p < .001), but in 60.20% of countries patients paid some or all of the cost. Funding source impacted capacity (p = .004), number of patients per exercise session (p < .001), personnel (p = .037), and functional capacity testing (p = .039). The median cost to serve 1 patient was $945.91PPP globally. In low and middle-income countries (LMICs), exercise equipment and stress testing were perceived as the most expensive delivery elements, with front-line personnel costs perceived as costlier in HICs (p = .003). Modifiable factors associated with higher costs included CR team composition (p = .001), stress testing (p = .002) and telemetry monitoring in HICs (p = .01), and not offering alternative models in LMICs (p = .02).
CONCLUSIONS CONCLUSIONS
Too many patients are paying out-of-pocket for CR, and more public funding is needed. Lower-cost delivery approaches are imperative, and include walk tests, task-shifting, and intensity monitoring via perceived exertion.

Identifiants

pubmed: 30414751
pii: S0167-5273(18)34389-4
doi: 10.1016/j.ijcard.2018.10.089
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Pagination

278-286

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Mahshid Moghei (M)

School of Kinesiology and Health Science, York University, Toronto, Canada.

Ella Pesah (E)

School of Kinesiology and Health Science, York University, Toronto, Canada.

Karam Turk-Adawi (K)

Department of Public Health, Qatar University, Al-Doha, Qatar.

Marta Supervia (M)

Gregorio Marañón Health Research Institute, Gregorio Marañón General University Hospital, Madrid, Spain.

Francisco Lopez Jimenez (FL)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, United States.

Ellen Schraa (E)

School of Kinesiology and Health Science, York University, Toronto, Canada.

Sherry L Grace (SL)

School of Kinesiology and Health Science, York University, Toronto, Canada; University Health Network, University of Toronto, Toronto, Canada. Electronic address: sgrace@yorku.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH